These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 15011781)

  • 1. Hematopoietic stem cell transplant as a platform for tumor immunotherapy.
    Fuchs EJ; Whartenby KA
    Curr Opin Mol Ther; 2004 Feb; 6(1):48-53. PubMed ID: 15011781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches to treating malignances with stem cell transplantation.
    Margolis J; Borrello I; Flinn IW
    Semin Oncol; 2000 Oct; 27(5):524-30. PubMed ID: 11049020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
    Mazumder A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic hematopoietic stem cell transplantation for solid tumors].
    Kanda Y
    Rinsho Ketsueki; 2004 Mar; 45(3):189-94. PubMed ID: 15103931
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for malignant tumors using combination of allogeneic intra-bone marrow-bone marrow transplantation, donor lymphocyte infusion and dendritic cells.
    Mukaide H; Adachi Y; Koike-Kiriyama N; Suzuki Y; Minamino K; Iwasaki M; Tsuda M; Nakano K; Koike Y; Shigematsu A; Kamiyama Y; Ikehara S
    Int J Oncol; 2007 Jun; 30(6):1309-15. PubMed ID: 17487350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation of the stem cell as a target for hematologic malignancies.
    Ballen KK; Becker PS; Stewart FM; Quesenberry PJ
    Semin Oncol; 2000 Oct; 27(5):512-23. PubMed ID: 11049019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.
    Slavin S
    Acta Haematol; 2005; 114(4):214-20. PubMed ID: 16269861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
    Espinoza-Delgado I; Childs RW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
    Har-Noy M; Slavin S
    Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
    Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
    Kline J; Subbiah S; Lazarus HM; van Besien K
    Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
    Owaidah TM
    Saudi Med J; 2003 Feb; 24(2):138-41. PubMed ID: 12682675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
    Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
    Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous hematopoietic stem cell transplantation for pediatric solid tumors.
    Hale GA
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):835-46. PubMed ID: 16221053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.
    Demirer T; Barkholt L; Blaise D; Pedrazzoli P; Aglietta M; Carella AM; Bay JO; Arpaci F; Rosti G; Gurman G; Niederwieser D; Bregni M;
    Nat Clin Pract Oncol; 2008 May; 5(5):256-67. PubMed ID: 18398414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.